AstraZeneca PLC on Monday said its cancer drug Enhertu has shown clinically meaningful and durable responses across multiple HER2-expressing advanced solid tumors in its DESTINY-PanTumor02 Phase II trial.
The Anglo-Swedish pharma major
AZN,
AZN,
said Enhertu–trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo–had met prespecified criteria for objective response rate and duration of response.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging,” said Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi.
Write to Elena Vardon at elena.vardon@wsj.com
